{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:06:20Z","timestamp":1773288380065,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40272-017-0258-9","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T06:17:27Z","timestamp":1502691447000},"page":"533-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tiotropium Bromide in Children and Adolescents with Asthma"],"prefix":"10.1007","volume":"19","author":[{"given":"Hengameh H.","family":"Raissy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. William","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"issue":"7","key":"258_CR1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jama.2010.104","volume":"303","author":"J Cleave Van","year":"2010","unstructured":"Van Cleave J, Gortmaker SL, Perrin JM. Dynamics of obesity and chronic health conditions among children and youth. JAMA. 2010;303(7):623\u201330.","journal-title":"JAMA."},{"key":"258_CR2","unstructured":"Centers for Disease Control and Prevention. 2014 National Health Interview Survey (NHIS) Data. Table\u00a03-1, current asthma population estimates\u2014in thousands by age, United States. \n                        https:\/\/www.cdc.gov\/asthma\/nhis\/2014\/table3-1.htm\n                        \n                    . Accessed June 2017."},{"issue":"3","key":"258_CR3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1081-1206(10)60713-2","volume":"98","author":"JK Schmier","year":"2007","unstructured":"Schmier JK, Manjunath R, Halpern MT, et al. The impact of inadequately controlled asthma in urban children on quality of life and productivity. Ann Allergy Asthma Immunol. 2007;98(3):245\u201351.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"258_CR4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4155\/cli.13.41","volume":"3","author":"HH Raissy","year":"2013","unstructured":"Raissy HH, Kelly HW. Inhaled corticosteroids: the last 5 years. Clin Investig. 2013;3(6):595\u2013602.","journal-title":"Clin Investig"},{"key":"258_CR5","unstructured":"National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Full Report of the Expert Panel: Guidelines for the diagnosis and management of asthma (EPR-3) 2007. \n                        https:\/\/www.nhlbi.nih.gov\/health-pro\/guidelines\/current\/asthma-guidelines\/full-report\n                        \n                    . Accessed  June 2017."},{"key":"258_CR6","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2017. \n                        http:\/\/ginasthma.org\/2017-gina-report-global-strategy-for-asthma-management-and-prevention\/\n                        \n                    . Accessed Aug 2017."},{"key":"258_CR7","first-page":"CD011721","volume":"1","author":"KM Kew","year":"2016","unstructured":"Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA\/ICS) versus LABA\/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;1:CD011721.","journal-title":"Cochrane Database Syst Rev."},{"key":"258_CR8","doi-asserted-by":"publisher","first-page":"CD011397","DOI":"10.1002\/14651858.CD011397.pub2","volume":"8","author":"DE Anderson","year":"2015","unstructured":"Anderson DE, Kew KM, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. Cochrane Database Syst Rev. 2015;8:CD011397. doi:\n                        10.1002\/14651858.CD011397.pub2\n                        \n                    .","journal-title":"Cochrane Database Syst Rev."},{"key":"258_CR9","doi-asserted-by":"publisher","first-page":"CD011437","DOI":"10.1002\/14651858.CD011437.pub2","volume":"7","author":"DJ Evans","year":"2015","unstructured":"Evans DJ, Kew KM, Anderson DE, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Cochrane Database Syst Rev. 2015;7:CD011437. doi:\n                        10.1002\/14651858.CD011437.pub2\n                        \n                    .","journal-title":"Cochrane Database Syst Rev."},{"key":"258_CR10","doi-asserted-by":"publisher","first-page":"CD011438","DOI":"10.1002\/14651858.CD011438.pub2","volume":"6","author":"KM Kew","year":"2015","unstructured":"Kew KM, Evans DJ, Allison DE, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev. 2015;6:CD011438. doi:\n                        10.1002\/14651858.CD011438.pub2\n                        \n                    .","journal-title":"Cochrane Database Syst Rev."},{"key":"258_CR11","unstructured":"SPIRIVA\u00ae RESPIMAT\u00ae (tiotropium bromide) inhalation spray, for oral inhalation [prescribing information]. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc.; 2017. \n                        http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Spiriva%20Respimat\/spirivarespimat.pdf\n                        \n                    . Accessed June 2017."},{"key":"258_CR12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1513\/pats.200504-043SR","volume":"2","author":"KE Belmonte","year":"2005","unstructured":"Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:297\u2013304.","journal-title":"Proc Am Thorac Soc."},{"key":"258_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40248-017-0099-y","volume":"12","author":"D Radovanovic","year":"2017","unstructured":"Radovanovic D, Santus P, Blasi F, Mantero M. Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscip Respir Med. 2017;12:17. doi:\n                        10.1186\/s40248-017-0099-y\n                        \n                    .","journal-title":"Multidiscip Respir Med."},{"key":"258_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12931-015-0175-9","volume":"16","author":"C Vogelberg","year":"2015","unstructured":"Vogelberg C, Moroni-Zentgraf P, Leonaviciute-klimantaviciene M, et al. A randomized dose-ranging study of tiotropium respimat in children with symptomatic asthma despite inhaled corticosteroids. Resp Res. 2015;16:20.","journal-title":"Resp Res."},{"key":"258_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.014","author":"SJ Szefler","year":"2017","unstructured":"Szefler SJ, Murphy K, Harper T, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017;. doi:\n                        10.1016\/j.jaci.2017.01.014\n                        \n                     (Epub 9 Feb 2017).","journal-title":"J Allergy Clin Immunol."},{"issue":"9","key":"258_CR16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.rmed.2014.06.011","volume":"108","author":"C Vogelberg","year":"2014","unstructured":"Vogelberg C, Engel M, Moroni-Zentgraf P, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomized dose-ranging study. Respir Med. 2014;108(9):1268\u201376.","journal-title":"Respir Med."},{"issue":"2","key":"258_CR17","doi-asserted-by":"crossref","first-page":"441.e8","DOI":"10.1016\/j.jaci.2016.01.011","volume":"138","author":"E Hamelmann","year":"2016","unstructured":"Hamelmann E, Bateman ED, Vogelberg C, et al. Tiotropium add-on therapy in adolescent with moderate asthma: a 1\u00a0year randomized controlled trial. J Allergy Clin Immunol. 2016;138(2):441.e8\u2013450.e8.","journal-title":"J Allergy Clin Immunol."},{"key":"258_CR18","doi-asserted-by":"crossref","unstructured":"Hamelmann E, Bernstein JA, Vandewalker M, et al. A randomized controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49(1).","DOI":"10.1183\/13993003.01100-2016"},{"key":"258_CR19","first-page":"CD007949","volume":"11","author":"BF Chauhan","year":"2015","unstructured":"Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2015;11:CD007949.","journal-title":"Cochrane Database Syst Rev."},{"key":"258_CR20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMoa1606356","volume":"375","author":"DA Stempel","year":"2016","unstructured":"Stempel DA, Szefler SJ, Pedersen S, VESTRI Investigators, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med. 2016;375:840\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"258_CR21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa1001278","volume":"362","author":"RF Lemanske Jr","year":"2010","unstructured":"Lemanske RF Jr, Mauger DT, Sorkness CA, Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362(11):975\u201385.","journal-title":"N Engl J Med."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-017-0258-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-017-0258-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-017-0258-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T07:10:23Z","timestamp":1510211423000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-017-0258-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1007\/s40272-017-0258-9","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]}}}